- Home
- SNSE vs ABP Comparison
SNSE vs ABP Comparison
Compare SNSE & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNSE | ABP |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2M | 12.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNSE | ABP |
|---|---|---|
| Price | $9.09 | $0.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $72.50 | N/A |
| AVG Volume (30 Days) | 55.1K | ★ 4.1M |
| Earning Date | 03-27-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 50.00 |
| 52 Week Low | $5.00 | $0.70 |
| 52 Week High | $18.35 | $34.65 |
Technical Indicators
Market Signals| Indicator | SNSE | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 44.76 | 19.87 |
| Support Level | $8.72 | $1.44 |
| Resistance Level | $9.44 | $2.89 |
| Average True Range (ATR) | 0.69 | 0.38 |
| MACD | -0.08 | -0.05 |
| Stochastic Oscillator | 34.62 | 2.29 |
Price Performance
Historical ComparisonAbout SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About ABP Abpro Holdings Inc
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.